Ensign Peak Advisors
HUMA icon

Ensign Peak Advisors’s Humacyte HUMA Stock Holding History

Ensign Peak Advisors’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-8,510
Closed -$28K – 1974
2022
Q3 		$28K Buy
8,510
+570
+7% +$2.19K ﹤0.01% 2300
2022
Q2 		$25K Hold
7,940
– – ﹤0.01% 2115
2022
Q1 		$56K Buy
+7,940
New +$46.2K ﹤0.01% 2113

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Ensign Peak Advisors's HUMA Position: Q4 2022 in Review

Ensign Peak Advisors sold out of Humacyte (HUMA) in Q4 2022, closing a stake of 8,510 shares — an estimated $28K sold.

Ensign Peak Advisors first reported a position in HUMA in Q1 2022 and held it in 3 quarters. The position peaked at $56K in Q1 2022. 75 funds tracked by Wall St. Rank hold HUMA as of Q4 2022.

  • Ensign Peak Advisors reported no remaining Humacyte position as of Q4 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 8,510 Humacyte shares in Q4 2022, an estimated $28K.
  • Ensign Peak Advisors first reported a position in Humacyte in Q1 2022 and held it in 3 quarters.
  • Ensign Peak Advisors's Humacyte position peaked at $56K in Q1 2022.
  • 75 funds tracked by Wall St. Rank held Humacyte as of Q4 2022.

Based on Ensign Peak Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.